Browse

PCI시술시 혈소판 당단백 GP IIb/IIIA 억제제(Abciximab) 투여의 경제적 가치
Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
김진현; 신상진; 김은주; 이영희
Issue Date
2007
Publisher
대한약학회 = The Pharmaceutical Society Of Korea
Citation
약학회지 51, 3 (2007)
Keywords
abciximabcost-effectiveness analysiscost-benefit analysisPCI
Abstract
This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the direct medical costs relevant to using abciximab were estimated from the NHI claims database. The results in terms of cost per life-year gained (LYG) and cost per QALY gained showed that abciximab was cost-effective enough to deserve its cost. Social net benefit resulting from abciximab in PCI was estimated to be 60-70 billion Won per year
ISSN
0377-9556
Language
Korean
URI
https://hdl.handle.net/10371/9645
Files in This Item:
Appears in Collections:
College of Nursing (간호대학)Dept. of Nursing (간호학과)Journal Papers (저널논문_간호학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse